2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
06/27/17ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board
Global Alzheimer’s Thought Leader to Assist in Exploring Potential for Nicotinamide Riboside in Brain and Neuronal Health IRVINE, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has appointed Dr.  Rudolph Tanzi, Vice-Chair of Neurology an... 
Printer Friendly Version
06/12/17ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN® in treating breast cancer
IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed a new, exclusive patent license and research agreement with The Scripps Research Institute (TSRI), gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie ... 
Printer Friendly Version
06/05/17ChromaDex Names World’s Leading Expert on Nicotinamide Riboside and NAD as Chief Scientific Advisor
Charles Brenner, PhD, an investigator on the forefront of metabolism research, to champion the advancement of NR and NAD boosting technologies IRVINE, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that Charles Brenner, PhD, the Roy J. Carver Ch... 
Printer Friendly Version
05/31/17NIAGEN® nicotinamide riboside launches into the functional food space
Barology’s Live Younger™ bar offers consumers a new way to help boost cellular metabolism and cellular energy production IRVINE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today the first launch of NIAGEN® nicotinamide riboside (NR) into the functi... 
Printer Friendly Version
05/25/17ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing
IRVINE, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader Mr. Li Ka-shing. Through Horizons Ventures, Mr. Li has inves... 
Printer Friendly Version
05/11/17ChromaDex Reports First Quarter 2017 Financial Results
Changes in Q1 and new investor set the foundation for success with NIAGEN® IRVINE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the quarter ended April 1, 2017. “I am very excited about the changes we have made the... 
Printer Friendly Version
05/04/17ChromaDex to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017
Company Will Host Investor Conference Call on Thursday, May 11, 2017 IRVINE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2017 financial results on Thursday, May 11, after the close of the financia... 
Printer Friendly Version
04/27/17ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing
IRVINE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into a securities purchase agreement for the sale of up to $25 million of its common stock in a private placement led by Hong Kong business leader Mr. Li Ka-shing. T... 
Printer Friendly Version
04/11/17ChromaDex to Showcase Novel Ingredient Science and Brand-Elevating Services at Ingredient Marketplace 2017
IRVINE, Calif., April 11, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it is bringing some of its top industry-advancing health and wellness ingredients and services to booth #H23 at Ingredient Marketplace 2017, taking place April 19-20 in Orlando, FL.  Ingr... 
Printer Friendly Version
03/29/17ChromaDex to Present at the Cowen and Company’s 3rd Annual Future of the Consumer Conference: Convergence & Disruption on April 4, 2017
IRVINE, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Co-Founder, Frank Jaksch, will present at Cowen and Company’s 3rd Annual Future of the Consumer Conference: Convergence & Disruption. The conferenc... 
Printer Friendly Version
03/28/17ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors
IRVINE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Steven D. Rubin, J.D. has joined the Company’s board of directors. Mr. Rubin, age 56, has served as OPKO Health, Inc.’s (NASDAQ:OPK) Executive Vice President – Administration since Ma... 
Printer Friendly Version
03/16/17ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%
Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22% IRVINE, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the year ended Dec. 31, 2016. “We finished 2016 on a strong note, generating 29% year over ... 
Printer Friendly Version
03/10/17ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017
Company Will Host Investor Conference Call on Friday, March 17, 2017 IRVINE, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its year end 2016 financial results on Thursday, March 16, after the close of the financial... 
Printer Friendly Version
02/23/17A Letter from the ChromaDex Chief Executive Officer
IRVINE, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- The following is issued on behalf of ChromaDex: Dear Fellow Shareholders: In January 2016, I issued a shareholder letter wherein I described in some detail my enthusiasm surrounding the enormous commercial opportunity we have with our patented NIAGEN® nicotinamide riboside (NR), a next-generation form of Vitamin B3 with what I believe has blockbuster potential in the emerging category of NAD+ (nicotinamide adenine dinucleotide) precursors. ... 
Printer Friendly Version
02/22/17Study Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy Induced by a Common Anticancer Agent
Early findings demonstrated in female rats may one day lead to reductions in the neuropathic pain experienced by millions of breast and ovarian cancer patients and survivors IRVINE, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC) an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Unive... 
Printer Friendly Version
02/21/17ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017
IRVINE, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it is bringing some of its top industry-advancing health and wellness products and services to booth #868 at Engredea 2017, taking place March 9-12 in Anaheim, CA.  ChromaDex is confident ... 
Printer Friendly Version
02/14/17ChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29%
Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million IRVINE, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today preliminary and unaudited revenue for the fourth quarter ended Decem... 
Printer Friendly Version
01/05/17ChromaDex Opens New State-of-the-Art Research and Development Center in Longmont
R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites IRVINE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Today, ChromaDex Corporation (https://www.chromadex.com/)  (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, is announcing the of... 
Printer Friendly Version
01/04/17ChromaDex to Present at the ICR Conference 2017 on January 11, 2017
IRVINE, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the ICR Conference 2017. The conference will be held January 9-11, 2017, at the JW Marriott Orlando Grande Lakes ... 
Printer Friendly Version